Dr. Richard Riedel, MD
Claim this profileDuke University Medical Center
Studies Sarcoma
Studies Soft Tissue Sarcoma
11 reported clinical trials
18 drugs studied
Area of expertise
1Sarcoma
Stage IV
Stage III
2Soft Tissue Sarcoma
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Richard Riedel, MD is currently running
INBRX-109
for Chondrosarcoma
This trial tests INBRX-109, a specially designed protein, in patients with a hard-to-treat type of bone cancer. The treatment helps the immune system target and kill cancer cells by attaching to a specific marker on these cells.
Recruiting0 awards Phase 26 criteria
Tazemetostat + Doxorubicin
for Sarcoma
The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue. Part 1 of this trial will evaluate the safety and the level of the study drug that the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compare for each of the study drug combinations how long participants live without their disease getting worse. The study drug is called tazemetostat. The study will test tazemetostat in combination with doxorubicin compared to placebo (dummy treatment) in combination with doxorubicin. Doxorubicin is a current front line treatment for epithelioid sarcoma
Recruiting1 award Phase 312 criteria
More about Richard Riedel, MD
Clinical Trial Related4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Richard Riedel, MD has experience with
- Placebo
- Doxorubicin HCl
- Tazemetostat
- AL102
- NC-6300
- Vimseltinib
Breakdown of trials Richard Riedel, MD has run
Sarcoma
Soft Tissue Sarcoma
Tumors
Epithelioid Sarcoma
Aggressive Fibromatosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Richard Riedel, MD specialize in?
Richard Riedel, MD focuses on Sarcoma and Soft Tissue Sarcoma. In particular, much of their work with Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Richard Riedel, MD currently recruiting for clinical trials?
Yes, Richard Riedel, MD is currently recruiting for 5 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Richard Riedel, MD has studied deeply?
Yes, Richard Riedel, MD has studied treatments such as Placebo, Doxorubicin HCl, Tazemetostat.
What is the best way to schedule an appointment with Richard Riedel, MD?
Apply for one of the trials that Richard Riedel, MD is conducting.
What is the office address of Richard Riedel, MD?
The office of Richard Riedel, MD is located at: Duke University Medical Center, Durham, North Carolina 27710 United States. This is the address for their practice at the Duke University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.